In reality, GLP-1 receptor agonists have been available for many years for the treatment of type 2 diabetes (Victoza, Trulicity, etc) and for weight loss (Saxenda), while tirzepatide is new in the last few years
After six months, both the treatment group and placebo group (who did not receive the supplement) saw significant improvements in their BMI
Here we derive a general expression equivalent to by considering the chemical state of a receptor catalyzed by phosphatase ( P ) with concentration P o and kinase ( K ) with concentration K o
Researchers studying the GH/IGF-1 axis for applications in muscle metabolism, bone density, connective tissue repair, and aging use this combination to achieve robust, sustained IGF-1 elevation in research models
Diabetologia 53 , S342 (2010)
Neither is "better" in a research sense, because the two are studied for different mechanistic questions